306 related articles for article (PubMed ID: 25850622)
1. Identification of Lipid Species Linked to the Progression of Non-Alcoholic Fatty Liver Disease.
Kawano Y; Nishiumi S; Saito M; Yano Y; Azuma T; Yoshida M
Curr Drug Targets; 2015; 16(12):1293-300. PubMed ID: 25850622
[TBL] [Abstract][Full Text] [Related]
2. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
3. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
[TBL] [Abstract][Full Text] [Related]
4. [Non-alcoholic fatty liver disease (NAFLD) /non-alcoholic steatohepatitis (NASH) and nutrition].
Ishii KA; Takamura T
Clin Calcium; 2016 Mar; 26(3):363-7. PubMed ID: 26923972
[TBL] [Abstract][Full Text] [Related]
5. Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis.
Alamri H; Patterson NH; Yang E; Zoroquiain P; Lazaris A; Chaurand P; Metrakos P
Anal Bioanal Chem; 2019 Feb; 411(4):885-894. PubMed ID: 30515538
[TBL] [Abstract][Full Text] [Related]
6. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH.
Amrutkar M; Cansby E; Nuñez-Durán E; Pirazzi C; Ståhlman M; Stenfeldt E; Smith U; Borén J; Mahlapuu M
FASEB J; 2015 Apr; 29(4):1564-76. PubMed ID: 25609431
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
Pierantonelli I; Svegliati-Baroni G
Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
[TBL] [Abstract][Full Text] [Related]
9. Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis.
Vergani L
Curr Med Chem; 2019; 26(19):3439-3456. PubMed ID: 28521680
[TBL] [Abstract][Full Text] [Related]
10. Lipid mediators of liver injury in nonalcoholic fatty liver disease.
Liangpunsakul S; Chalasani N
Am J Physiol Gastrointest Liver Physiol; 2019 Jan; 316(1):G75-G81. PubMed ID: 30383414
[TBL] [Abstract][Full Text] [Related]
11. Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD.
Mashek DG
Mol Metab; 2021 Aug; 50():101115. PubMed ID: 33186758
[TBL] [Abstract][Full Text] [Related]
12. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action.
Scorletti E; Byrne CD
Mol Aspects Med; 2018 Dec; 64():135-146. PubMed ID: 29544992
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease: Insights from sphingolipidomics.
Montefusco DJ; Allegood JC; Spiegel S; Cowart LA
Biochem Biophys Res Commun; 2018 Oct; 504(3):608-616. PubMed ID: 29778532
[TBL] [Abstract][Full Text] [Related]
14. Molecular drivers of non-alcoholic steatohepatitis are sustained in mild-to-late fibrosis progression in a guinea pig model.
Ipsen DH; Skat-Rørdam J; Tsamouri MM; Latta M; Lykkesfeldt J; Tveden-Nyborg P
Mol Genet Genomics; 2019 Jun; 294(3):649-661. PubMed ID: 30759275
[TBL] [Abstract][Full Text] [Related]
15. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model.
Gorden DL; Ivanova PT; Myers DS; McIntyre JO; VanSaun MN; Wright JK; Matrisian LM; Brown HA
PLoS One; 2011; 6(8):e22775. PubMed ID: 21857953
[TBL] [Abstract][Full Text] [Related]
16. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
17. A lipidomic analysis of nonalcoholic fatty liver disease.
Puri P; Baillie RA; Wiest MM; Mirshahi F; Choudhury J; Cheung O; Sargeant C; Contos MJ; Sanyal AJ
Hepatology; 2007 Oct; 46(4):1081-90. PubMed ID: 17654743
[TBL] [Abstract][Full Text] [Related]
18. p53 as a double-edged sword in the progression of non-alcoholic fatty liver disease.
Yan Z; Miao X; Zhang B; Xie J
Life Sci; 2018 Dec; 215():64-72. PubMed ID: 30473026
[TBL] [Abstract][Full Text] [Related]
19. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.
Alonso C; Fernández-Ramos D; Varela-Rey M; Martínez-Arranz I; Navasa N; Van Liempd SM; Lavín Trueba JL; Mayo R; Ilisso CP; de Juan VG; Iruarrizaga-Lejarreta M; delaCruz-Villar L; Mincholé I; Robinson A; Crespo J; Martín-Duce A; Romero-Gómez M; Sann H; Platon J; Van Eyk J; Aspichueta P; Noureddin M; Falcón-Pérez JM; Anguita J; Aransay AM; Martínez-Chantar ML; Lu SC; Mato JM
Gastroenterology; 2017 May; 152(6):1449-1461.e7. PubMed ID: 28132890
[TBL] [Abstract][Full Text] [Related]
20. Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis.
Musso G; Cassader M; Paschetta E; Gambino R
Gastroenterology; 2018 Aug; 155(2):282-302.e8. PubMed ID: 29906416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
